Harvard Health Letter

Changing the cardiovascular prevention game

Results of the JUPITER trial showed that people with low LDL cholesterol but with a high C-reactive protein level who took the statin rosuvastatin had a dramatic decrease in risk of serious cardiovascular events.

To continue reading this article you must be registered.

Get Licensed Content to Harvard Health

If you are interested in licensing content from Harvard Health Publications, please contact us using our online form. Our licensing and business development professionals will help you leverage consumer health content from Harvard Medical School as a clear differentiator in helping achieve your business goals.

Contact Us

Customer Log In